{
    "clinical_study": {
        "@rank": "73810", 
        "arm_group": {
            "arm_group_label": "AutoloGel", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment"
        }, 
        "brief_summary": {
            "textblock": "The aim of this trial is to demonstrate the effectiveness of complete wound healing in a\n      prospective, open-label, cohort-controlled trial in which venous leg ulcers (VLU)n will be\n      treated using AutoloGel and case-matched against a concurrent cohort of patients receiving\n      undefined Usual and Customary Care (UCC)"
        }, 
        "brief_title": "A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Leg Ulcer", 
        "condition_browse": {
            "mesh_term": [
                "Leg Ulcer", 
                "Ulcer", 
                "Varicose Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "Recurrence of ulcers in the leg is common; two-thirds of patients are likely to experience\n      recurring ulcers after the first ulcer. While treatment of the underlying venous disease,\n      depending on the mode of treatment, can lower the recurrence rate in many patients, it does\n      not affect recurrence. AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment\n      of non-healing chronic wounds. The aim of this trial is to demonstrate the effectiveness,\n      measured as complete wound healing, in a prospective, open-label trial in which venous leg\n      ulcers will be treated using AutoloGel and standard of care and case-matched against a\n      concurrent cohort of patients receiving undefined Usual and Customary Care"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Medicare/Medicaid eligible\n\n          2. \u226518 years of age\n\n          3. Proven venous disease\n\n          4. The largest non-healing wound, if multiple wounds are present, or the single wound to\n             be treated (Index Ulcer) that is located between and including the knee and the ankle\n\n          5. For subjects with potentially multiple eligible VLUs, the largest ulcer will be\n             selected. There must be at least 4 cm between the Index Ulcer and other ulcers; if\n             all ulcers are closer than 4 cm, the subject should not be enrolled (screen failure)\n\n          6. Debrided ulcer size between 2 cm2 and 200 cm2\n\n          7. Demonstrated adequate compression regimen\n\n          8. Duration \u2265 1 month at first visit\n\n          9. Subject must be willing to comply with the Protocol, which will be assessed by\n             enrolling clinician.\n\n        Exclusion Criteria:\n\n          1. Subjects known to be sensitive to AutoloGel components (calcium chloride, thrombin,\n             ascorbic acid) and/or materials of bovine origin\n\n          2. Presence of another wound that is concurrently treated and might interfere with\n             treatment of index wound by AutoloGel\n\n          3. Ulcer not of VLU pathophysiology (e.g., pure diabetic, vasculitic, radiation,\n             rheumatoid, collagen vascular disease, pressure, or arterial etiology)\n\n          4. Any malignancy other than non-melanoma skin cancer\n\n          5. Subjects who are cognitively impaired and do not have a healthcare proxy\n\n          6. Serum albumin of less than 2.5 g/dL\n\n          7. Plasma Platelet count of less than 100 x 109/L\n\n          8. Hemoglobin of less than 10.5 g/dL\n\n          9. Subject has inadequate venous access for repeated blood draw required for AutoloGel\n             Administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "385", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817543", 
            "org_study_id": "CM003"
        }, 
        "intervention": {
            "arm_group_label": "AutoloGel", 
            "description": "Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds", 
            "intervention_name": "AutoloGel", 
            "intervention_type": "Device", 
            "other_name": "AutoloGel System"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "venous leg ulcers", 
            "non healing wounds"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "location": [
            {
                "contact": {
                    "email": "rinoie@att.net", 
                    "last_name": "Sato Rinoie, DPM", 
                    "phone": "(626) 821 9323"
                }, 
                "facility": {
                    "address": {
                        "city": "Arcadia", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91007"
                    }
                }, 
                "investigator": {
                    "last_name": "Sato Rinoie, DPM", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bmarcus@hyperbarxs.com", 
                    "last_name": "Belinda Marcus, MD", 
                    "phone": "770-771-6400"
                }, 
                "facility": {
                    "address": {
                        "city": "Cumming", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "HyperBarxs at Northside Forsyth"
                }, 
                "investigator": {
                    "last_name": "Belinda Marcus, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers", 
        "overall_contact": {
            "email": "jearabino@cytomedix.com", 
            "last_name": "Jackie Earabino, RN"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary endpoint is time to wound healing after 12 weeks com pared with case matched controls receiving standard of care. Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart (FDA Guidance for Industry Chronic Cutaneous Ulcer and Burn Wounds \u2500 Developing Products for Treatment, 2006).", 
            "measure": "Time to wound closure", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817543"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Comparison of proportion of wounds healed over 12 weeks", 
                "measure": "Proportion of wounds healed", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Frequency of ulcer recurrence over a 1 year period post treatment; recurrence is defined as any new ulcer appearing on the leg after the index ulcer has healed.", 
                "measure": "Frequency of ulcer recurrence", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Change in mean Quality of Life with Chronic Wounds (W-QOL) score between baseline and at 12 weeks", 
                "measure": "Change in Quality of Life with Chronic Wounds (W-QOL) Score", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Frequency and severity of treatment emergent adverse events", 
                "measure": "Number of patients with adverse events as a measure of tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Cytomedix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cytomedix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}